Single ascending dose study of the safety, tolerability, and pharmacokinetics of GAP-134 administered intravenously as a 24-hour infusion to healthy subjects
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2008
At a glance
- Drugs Danegaptide (Primary)
- Indications Arrhythmias
- Focus Adverse reactions
- Sponsors Wyeth
- 12 Mar 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2007 The expected completion date for this trial is now 31 Dec 2007.
- 04 Oct 2007 Status change from initiated to recruiting.